Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T13714L |
GRK2-IN-1 hydrochloride (2055990-90-2 free base)
GRK2-IN-1 hydrochloride |
GRK | GPCR/G Protein |
GRKs-IN-1 hydrochloride has remarkable potency against and selectivity for G protein-coupled receptor kinase 2 GRK2 (IC50: 130 nM) and GRK5 (IC50: 7.1 μM). | |||
T25464 |
GRK2 Inhibitor
βARK1 Inhibitor |
||
GRK2 Inhibitor is an inhibitor of β-Adrenergic Receptor Kinase 1 (β ARK1). | |||
T13714 |
CCG258208
GRK2-IN-1 |
GRK | GPCR/G Protein |
GRKs-IN-1 has remarkable potency against and selectivity for G protein-coupled receptor kinase 2 GRK2 (IC50: 130 nM) and GRK5 (IC50: 7.1 μM). | |||
T79913 |
GRK2 Inhibitor 2
|
||
GRK2 Inhibitor 2 (Compound 8h) 作为一种高效的抑制剂,对GRK2有显著的抑制活性(IC50: 19 nM),同样对Aurora-A也表现出抑制作用(IC50: 137 nM)。该化合物能增强GRK2过表达的HEK293细胞中β-AR介导的cAMP积累。此外,GRK2 Inhibitor 2适用于充血性心力衰竭(HF)的相关研究。 | |||
T24850 |
Takeda103A
CMPD103A,Takeda-103A,Takeda-103-A,CMPD-103A,Takeda 103 A |
GRK | GPCR/G Protein |
Takeda103A (CMPD103A) 是 GRK2抑制剂。G 蛋白偶联受体是许多生理过程的核心。Takeda103A 对研究心力衰竭具有潜在的研究价值。 | |||
T75935 |
GRK2i TFA
|
||
GRK2i TFA 是一个 GRK2抑制多肽,特异性抑制 Gβγ 活化 GRK2。 GRK2i TFA 对应于 Gβγ结合域,并作为细胞 Gβγ 拮抗剂。 | |||
TP2025 |
GRK2i
|
||
GRK2 inhibitory polypeptide that specifically inhibits Gβγ activation of GRK2. Corresponds to the Gβγ-binding domain and acts as a cellular Gβγ antagonist. | |||
T3498 |
CCG215022
|
GRK; PKA | GPCR/G Protein; Tyrosine Kinase/Adaptors |
CCG215022 是 G 蛋白偶联受体激酶抑制剂,能够作用于 GRK2 (IC50:0.15±0.07 μM),GRK5 (IC50:0.38±0.06 μM) 和 GRK1 (IC50:3.9±1 μM)。 | |||
T14989 |
CMPD101
|
ROCK; GRK; PKC | Cell Cycle/Checkpoint; Chromatin/Epigenetic; Cytoskeletal Signaling; GPCR/G Protein; Stem Cells |
CMPD101 是膜透性的 GRK2/3高选择性小分子抑制剂,IC50分别为 18 nM 和 5.4 nM。它针对 GRK1、GRK5 ROCK-2 和 PKCα 的选择性较小,IC50值分别为 3.1 μM,2.3 μM,1.4 μM 和 8.1 μM,可研究心衰疾病。 | |||
T8913 |
1-(2,3-DIHYDRO-BENZO[1,4]DIOXIN-6-YL)-5-OXO-PYRROLIDINE-3-CARBOXYLIC ACID
1-(2,3-二氢-1,4-苯并二氧杂芑-6-基)-5-氧代吡咯烷-3-羧酸 |
GRK | GPCR/G Protein |
1-(2,3-DIHYDRO-BENZO[1,4]DIOXIN-6-YL)-5-OXO-PYRROLIDINE-3-CARBOXYLIC ACID 靶向 GRK2。 | |||
T1636L |
Paroxetine hydrochloride hemihydrate
Paroxetine Hydrochloride,Paxil,Paroxetine HCl,Seroxat |
5-HT Receptor | GPCR/G Protein; Neuroscience |
Paroxetine hydrochloride hemihydrate (Paxil) 是一种抗抑郁药,为高效的五羟色胺再摄取抑制剂,能抑制 GRK2 活性,IC50 为 14 μM。 | |||
T3513 |
GSK180736A
GSK180736 |
ROCK; GRK; PKA | Cell Cycle/Checkpoint; Cytoskeletal Signaling; GPCR/G Protein; Stem Cells; Tyrosine Kinase/Adaptors |
GSK180736A 是 Rho 相关卷曲螺旋激酶 1 (ROCK1) 抑制剂,IC50值为 100 nM。它也是选择性的ATP-竞争性 G 蛋白偶联受体激酶 2 抑制剂,IC50值为 0.77 μM,其选择性比其他 GRK 高 100 倍以上。 | |||
T1636 |
Paroxetine hydrochloride
Paroxetine HCl,BRL29060 hydrochloride,FG-7051,BRL29060A,盐酸帕罗西汀 |
5-HT Receptor; Serotonin Transporter; GRK; AChR; Autophagy | Autophagy; GPCR/G Protein; Neuroscience |
Paroxetine hydrochloride (Paroxetine HCl) 是一种血清素摄取抑制剂,能抑制 GRK2 活性,IC50值为 14 μM。它可研究抑郁症。 | |||
T27479 |
GSK466317A
GSK-466317A,GSK 466317A |
||
GSK466317A is a GRK2 inhibitor. | |||
T27472 |
GSK317354A
GSK 317354A,GSK-317354A |
||
GSK317354A is a GRK2 inhibitor. | |||
T63340 |
CCG-273220
|
||
CCG-273220 是 G 蛋白偶联受体 (GPCR) 激酶 5 (GRK5) 共价抑制剂 (IC50: 220 nM)。CCG-273220 可以共价结合GRK5亚家族特异性残基 Cys474 ,而对GRK5的选择性比 GRK2 高。 | |||
T63411 |
CCG258747
|
||
CCG258747 是一种新型的、选择性的 GRK2 亚家族抑制剂。 | |||
T79312 |
FGH31
|
Dopamine Receptor | GPCR/G Protein; Neuroscience |
FGH31 (Compound 24) 作为选择性GRK2依赖的dopamine D4激动剂,显示出Ki值为1.6 nM的高亲和力,并能部分激活β-arrestin。 | |||
T62986 |
CCG-271423
|
||
CCG-271423 是一种有效的、选择性的 GRK5 抑制剂,作用于 GRK5 (IC50: 0.0021 μM) 和 GRK2 (IC50: 44 μM)。CCG-271423 能够降低 Ca2+瞬态,抑制心肌细胞收缩能力。 | |||
T63203 | GRK5-IN-4 | ||
GRK5-IN-4 是选择性的、有效的、共价 GRK5(G 蛋白偶联受体激酶 5) 抑制剂(IC50: 1.1 μM)。GRK5-IN-4 对 GRK5 的选择性是 GRK2 的90倍。GRK5-IN-4 能够用于研究心力衰竭。 | |||
T35875 | CCG258208 hydrochloride | ||
GRKs-IN-1 hydrochloride, Compound 14as, has remarkable potency against and selectivity for G protein-coupled receptor kinase 2 GRK2 (IC50=130 nM) and GRK5 (IC50=7.1 μM).GRKs-IN-1 hydrochloride is a derivative 14as of paroxetine, shows a 100-fold improvement in cardiomyocyte contractility assays over paroxetine[1]. [1]. Waldschmidt HV, et al. Structure-Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2Inhibitors Based on Paroxetine. J Med Chem. 2017 Apr 13;60(7):305... |